Celestial Biolabs Limited is an India-based biopharmaceutical company. The Company is engaged in the production and supply of herbal and feed supplement formulations. The Company's products portfolio includes health products for men, women and children. Its product categories include herbal, enzymes and nutraceuticals. Its herbal product category includes products, such as proprietary products and classical products. Proprietary products include Biovita, Cadalmin GAe, Cel-Digest, Bioliv, Rhumacel, Cel-Clear, Biopower Gold, Bio-Dnorm, Dermacel, Gynocel, Healthone, Relifin and C-Kaps. Its Classical products include Lavan Bhaskar Churna, Talishadi Churna, Sitopaladi Churna, Sring Bhasma, Bala Chaturbhadrika Churna and Chandraprabha Vat. Its enzymes products include CELZYME-P, CELZYME-L, CELZYME-PMAX, CELZYME-DMAX, CELZYME-OXI, CELZYME-TEXDS, CELZYME-TEXWASH, CELZYME-DSB, CELZYME-Peroxide, CELZYME-RECASE, CELZYME-Phytase, CELZYME-CELCAF, CELZYME-Maxmol and CELZYME-Amyl.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.